10x Genomics (10x Genomics) Debt-to-Revenue : 0.13 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

10x Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.5 Mil. 10x Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $83.8 Mil. 10x Genomics's annualized Revenue for the quarter that ended in Dec. 2023 was $735.9 Mil. 10x Genomics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.13.

10x Genomics Debt-to-Revenue Historical Data

The historical data trend for 10x Genomics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Debt-to-Revenue Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.12

0.21

0.17

0.18

0.15

10x Genomics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.15	0.19	0.17	0.16	0.13

Competitive Comparison of 10x Genomics's Debt-to-Revenue

For the Health Information Services subindustry, 10x Genomics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

10x Genomics's Debt-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Debt-to-Revenue falls into.

10x Genomics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

10x Genomics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.521	+	83.849)	/	618.727
	=	0.15

10x Genomics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.521	+	83.849)	/	735.916
	=	0.13

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

10x Genomics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics (10x Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Executives

Serge Saxonov	director, 10 percent owner, officer: Chief Executive Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur	officer: Chief Commercial Officer	C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson	director, officer: See Remarks	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear	officer: Chief Financial Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel	director	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen	director	THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield	officer: Chief Commercial Officer	6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts	director	C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc	10 percent owner	2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006